Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Pragma Gestao DE Patrimonio Ltd.

Pragma Gestao DE Patrimonio Ltd. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 69.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,000 shares of the medical research company's stock after purchasing an additional 4,500 shares during the period. Thermo Fisher Scientific makes up approximately 3.2% of Pragma Gestao DE Patrimonio Ltd.'s investment portfolio, making the stock its 12th biggest holding. Pragma Gestao DE Patrimonio Ltd.'s holdings in Thermo Fisher Scientific were worth $5,723,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Proficio Capital Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock valued at $396,810,000 after purchasing an additional 761,649 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $377,901,000. Lindsell Train Ltd purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $211,858,000. Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 15.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,810,128 shares of the medical research company's stock valued at $1,461,913,000 after purchasing an additional 366,191 shares during the period. Finally, Amundi lifted its position in shares of Thermo Fisher Scientific by 13.5% in the 4th quarter. Amundi now owns 2,860,847 shares of the medical research company's stock worth $1,556,689,000 after purchasing an additional 340,263 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares of the company's stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $8.01 on Monday, hitting $492.15. The company had a trading volume of 844,219 shares, compared to its average volume of 1,611,644. The company has a market capitalization of $185.67 billion, a PE ratio of 29.78, a PEG ratio of 2.99 and a beta of 0.79. The company's fifty day moving average price is $541.60 and its 200-day moving average price is $551.84. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 12-month low of $484.69 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific's dividend payout ratio is presently 10.41%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TMO. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a report on Friday, January 31st. Bank of America decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Morgan Stanley upped their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, Raymond James restated an "outperform" rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.